Patient must not have an antecedent hematologic disorder
Ages > 50 years with hematologic malignancies treatable by related or unrelated HCT
Acceptable hematologic status:
Acceptable hematologic status:
Platelets >= 75,000/mcL (>= 50,000 for patients with hematologic malignancies)
Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)
Acceptable hematologic status
Participants with hematologic lymphoma
Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)
Participants with hematologic malignancies
Acceptable hematologic status at Screening
Have current hematologic malignancies, acute or chronic leukemia.
Evidence of relapse or progression of hematologic malignancy at the time of study enrollment.
Confirmed advanced hematologic malignancies; Phase 1:
Hematologic malignancies other than lymphomas.
Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy
Hematologic malignancies other than lymphomas.
Ages > 50 years with hematologic malignancies treatable by unrelated hematopoietic cell transplant (HCT)
Any history of or current hematologic malignancy
Current hematologic malignancies.
Concurrent hematologic or non-hematologic malignancy requiring treatment
Patients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorder
Patients must be diagnosed with a high-risk and/or advanced hematologic malignancy defined as one of the following
Germ cell or hematologic malignancies
Hematologic malignancy
Loss of complete hematologic response (CHR)
Patients with history of hematologic malignancy
Patients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorder
Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma and secondary amyloidosis)
Any history of or current hematologic malignancy
INCLUSION CRITERIA FOR ENROLLMENT: Active relapse involving the bone marrow of a hematologic malignancy >= 6 months after allogeneic hematopoietic cell transplant (alloHCT) employing PTCy as GVHD prophylaxis
Remission of any acute hematologic malignancy or adequate disease control for chronic malignancies
Treatment for non-hematologic malignancy greater than 6 months prior to enrollment is acceptable
Patients must have histo-pathologically confirmed diagnosis of hematologic malignancy (leukemia or lymphoma); patients to be considered will either have resistant/refractory hematologic malignancies (disease exceeding 5% by morphology or with measurable extramedullary diseases: e.g. nodal disease or chloroma) or have relapsed following an initial allogeneic HSCT; alternatively, they will have a hematologic malignancy where allogeneic HSCT is indicated and their disease is in a state of remission, but they lack a well matched donor: related, unrelated donor (URD) or umbilical cord blood (UCB) HSC source (less than 7 of 8 URD match, less than 4 of 6 UCB match and/or less than 2 x10^5 CD 34+ HSC/kg in a matched UCB product); patients between 19 and 24 years of age will have been previously diagnosed and cared for by a Pediatric Oncologist
Uncontrolled, non-hematologic malignancy requiring active treatment
Hematologic or lymphoid malignancy
Patients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorder
Acceptable hematologic status
Patients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorder
Patients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorder
Hematologic malignancies other than lymphomas.
Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy
Other hematologic/biochemistry requirements, as per protocol
Patient must have hematologic malignancy that meets institutional eligibility requirements for cord blood transplant
Patients receiving any other standard or investigational treatment for their hematologic malignancy
Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma or secondary amyloidosis)
Untreated first hematologic relapse is defined as:
Subject is in second or later hematologic relapse or has received salvage therapy for refractory disease
Part 1: solid tumors or lymphomas, or hematologic malignancies
Acceptable hematologic status:
Diagnosis of any of the following hematologic malignancies:
Hematologic and Non-hematologic exclusion criteria before start of therapy.
Patients in CRi must have evidence of hematologic recovery after prior therapy to at least: platelets >= 75 x 10^9/L
Patients with history of hematologic malignancies who have received at least 2 lines of standard chemoimmunotherapy and have persistent disease
?1 prior systemic hematologic therapy for a free light chain (FLC) producing hematologic malignancy underlying the initial diagnosis of AL amyloidosis with at least a partial FLC response (PR, VGPR, CR) to treatment deemed stable and not requiring further treatment
Patients with high risk hematologic malignancies, including those with induction failure and in relapse
Presence of < 4% blasts on hematologic studies
Patients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorder
Active morphologic relapse/progression of hematologic malignancy post transplantation.
Splenomegaly or history of proliferative hematologic disease
Ages > 50 years with hematologic malignancies treatable by unrelated hematopoietic cell transplant (HCT)
Patients with the following hematologic malignancies will be permitted although other diagnoses can be considered if approved by Patient Care Conference (PCC) and the principal investigators:
Diagnosis of hematologic malignancy and at least one of the criteria as specified above
Subjects must have a histopathologically confirmed diagnosis of an advanced non-hematologic malignancy or lymphoma or indolent NHL/CLL.
Patients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorder or complications there from
Concurrent non-hematologic malignancies requiring treatment.
Histopathologically confirmed diagnosis of a metastatic non-hematologic malignancy.
For the hematologic malignancy patients, blood count values cited above do not apply.
Other high risk hematologic malignancies to be approved by 2 or more hematology/oncology and bone marrow transplant (BMT) physicians
?1 prior systemic plasma cell dyscrasia therapy with at least a partial hematologic response
Any prior history of other hematologic malignancy besides FL or myelodysplasia
Newly Diagnosed Secondary AML age <60 years and ?76 to 80 years, defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes [MDS], myeloproliferative disease [MPD]or history of cytotoxic treatment for non-hematologic malignancy)
Evidence of significant hepatic, hematologic, or immunologic disease.
Antecedent hematologic disease
Hematologic:
Receiving any other standard treatment for their hematologic malignancy.
Hematologic status:
Therapy with any other standard or investigational treatment for hematologic malignancy (except hydroxyurea, as mentioned in the inclusion criteria)
Uncontrolled concurrent illness including: other hematologic or non-hematologic malignancy, active infection, or uncontrolled diabetes
Have known current hematologic malignancies or acute or chronic leukemia
Newly Diagnosed Secondary AML defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes [MDS], myeloproliferative disease [MPD]or history of cytotoxic treatment for non-hematologic malignancy)
Patients with history of hematologic disease, including myelodysplasia or bone marrow malignancies
A diagnosis of any hematologic or solid malignancy
Phase I: Having a non-hematologic malignancy reason for undergoing transplantation (e.g. aplastic anemia)
Admission to the MSKCC Adult BMT service for an outpatient HSCT for a hematologic malignancy
Patients with hematologic malignancy receiving care (chemotherapy, immunotherapy, targeted agents, bone marrow transplant, or other) for their hematologic malignancy at the Ohio State University
Hematologic malignancy
Hematologic malignancies including acute and chronic leukemias, myelodysplastic syndromes, and myeloma
Patients diagnosed with a hematologic malignancy
Adult patients with hematologic malignancy admitted to Massachusetts General Hospital (MGH) HSCT are eligible for the study
A total bilirubin of less than 2.5 mg/dL, unless these values are due to underlying hematologic malignancy
Received a transplant at a consortium center for a hematologic malignancy or myelodysplasia
Active hematologic malignancy (cancer that begins in blood-forming tissue, such as leukemia or lymphoma)
Evidence of hematologic malignancy or disease relapse post-transplant (stable mixed chimerisms is permitted)
FOR THE 31 SUBJECTS ENROLLED IN YEAR 1: Evidence of hematologic malignancy or disease relapse post-transplant (stable mixed chimerisms is permitted)
Evidence of hematologic malignancy or disease relapse post-transplant (stable mixed chimerisms are permitted)
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Non-hematologic malignancy with a life expectancy of < 5 years
Patients must have a hematologic malignancy treatable by nonmyeloablative HCT; the following diseases will be permitted although other diagnoses can be considered if approved by Patient Care Conference (PCC) and the principal investigator:
Any of the following hematologic malignancies:
Hematologic malignancies with the exception of lymphoma
Any of the following hematologic malignancies:
Non-hematologic malignancy within prior three (3) years.
No current or history of a hematologic malignancy is allowed, including subjects who have undergone a bone marrow transplant.
Active malignancy (other than BRAF V600 mutation-negative melanoma) or malignancy within 3 years
Patients being actively treated for a secondary malignancy
Active secondary malignancy
Secondary malignancy.
A patient with a known other malignancy is eligible if there is a negligible risk for disease progression or death within one year, there is no active ongoing treatment for this malignancy, and the malignancy and/or any anticipated future treatments would not interfere with protocol-mandated evaluations at 1 year
Active malignancy other than the one for which AB-110 transplant is being performed within 12 months of enrollment.
Other active malignancy that warrants systemic therapy
No other active malignancy
Persistence/relapse at the time of study entry of the primary malignancy for which the transplant was performed, or any other active malignancy; patients with a history of relapsed malignancy who have achieved a remission at the time of evaluation for study participation will not be excluded
Patients must NOT have an active malignancy other than CD19+ leukemia
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
Other active malignancy
No active secondary malignancy
No other active malignancy
Subjects must NOT have an active malignancy other than CD22+ leukemia
No other active malignancy
Evidence of active malignancy other than CD19+ malignancy
No other active malignancy
Other active malignancy receiving systemic therapy.
Active malignancy
Active CNS malignancy
Have active malignancy with the exception of nonmelanoma skin cancer, as determined by the investigator. Subjects who experience relapse or progression of their underlying malignancy (for which HSCT was performed), as determined by the investigator, are not to be enrolled.
Presence of relapsed primary malignancy, or who have been treated for relapse after the alloHSCT was performed, or who may require rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse.
Does not have any other active malignancy other than the one for which this transplant is indicated
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
Active treatment of a separate malignancy
Patients with prior malignancy successfully treated who are currently stable and on no active treatment are eligible
Patients with active secondary malignancy unless approved by the study chair
No other active malignancy
No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ; patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies
Patient does NOT have an active malignancy other than NB
Active and uncontrolled relapse of malignancy.
Active and uncontrolled relapse of malignancy
Active and uncontrolled relapse of malignancy
Any other active malignancy
Patients with active secondary malignancy will not be eligible unless approved by the principal investigator
Active and uncontrolled relapse of malignancy
RECIPIENT: Presence of active malignancy in another organ system other than the hematopoietic, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancy
Presence of active malignancy in another organ system other than the hematopoietic system, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancy
Has another active systemic malignancy treated with chemotherapy within 12 months before baseline (C1D1).
Patient has another active malignancy
Any active secondary malignancy
History of tuberous sclerosis, lymphangioleiomyomatosis (LAM) or any active malignancy
Patients with another uncontrolled malignancy; patients with a previous malignancy, treated curatively and without evidence of disease relapse are eligible
Other active malignancy
Active secondary malignancy
Any active malignancy within 3 years that may alter the course of esophageal cancer; (apparently cured localized malignancy or advanced, but indolent malignancy with significantly more favorable prognosis are allowed)
No active co-existing malignancy with life expectancy less than 12 months due to that malignancy
History of another active uncontrolled malignancy at the time of study enrollment
Patients must not have an active secondary malignancy
No other active malignancy
Patients with more than one active malignancy at the time of enrollment.
Subjects with another active malignancy
No active or co-existing malignancy (other than ALL or lymphoblastic lymphoma) with life expectancy less than 12 months due to that malignancy
Presence of active malignancy from an organ system other than hematopoietic
Other active malignancy
Active malignancy with the exception of any of the following:
Subjects being actively treated for a secondary malignancy.
Active treatment for a secondary malignancy
Secondary malignancy, with the exception of:
Has active secondary malignancy that requires treatment.
Undergoing active treatment for a secondary malignancy.
Active malignancy other than the one for which the UCB transplant is being performed within 12 months of enrollment.
Active malignancy besides HNSCC or primary skin basal cell carcinoma; (patients with a concomitant malignancy that has not progressed within 12 months of study entry are eligible)
Patients with more than one type of active malignancy; an active malignancy is defined as one that is being treated with therapeutic intent and for which survival may be impacted, within 3 years of enrollment
Subjects being actively treated for a secondary malignancy.
Other currently active malignancy
Other active malignancy
Patients must not have another, non-breast, active malignancy that requires treatment
Other active malignancy that requires therapy
Active and uncontrolled relapse of malignancy
Presence of an active secondary malignancy.
Patients with active secondary malignancy will not be eligible
Does not have any other active malignancy other than the one for which this transplant is indicated
No other known active secondary primary malignancy
Active and uncontrolled relapse of malignancy
Patients with active secondary malignancy will not be eligible unless approved by the principal investigator (PI)
Does not have any other active malignancy other than the one for which this transplant is indicated
Any other malignancy that requires active treatment
No other currently active malignancy.
Other active malignancy.
Untreated active, or inappropriately/inadequately treated breast malignancy, without surgical treatment
Secondary malignancy
Patients with evidence of persistent or active malignancy
Another active malignancy
Patients with active malignancy; patient undergoing active treatment for malignancy in the adjuvant setting are eligible; treatment can include chemotherapy, targeted therapy or anti-hormonal therapy
Active and uncontrolled relapse of malignancy
Active malignancy, metastatic disease, or anyone undergoing treatment for malignancy
Women with an active malignancy
Patients diagnosed with secondary hepatic malignancy
